Sun Genomics expands testing options for its Floré Gut Health product suite

The founder and CEO of the personalized probiotics company will discuss the new offerings, in addition to how digital medicine has improved gut health, at the Digital Medicine and Medical Technology Showcase

Flora Collection

A collection of four boxes of Sun Genomics products

A collection of four boxes of Sun Genomics products

SAN DIEGO, Jan. 10, 2022 (GLOBE NEWSWIRE) — Genomic Sun, creator of Floré, the world’s only fully personalized precision probiotic, today announced that it is expanding gut health testing options for its Floré product line in 2022. Company Founder and CEO Sunny Jain , will discuss the expansion during his presentation at the virtual fair Showcase of digital medicine and medical technologies January 10-19, 2022. Registered participants may access the application at the Sun Genomics Company recorded presentation at their convenience.

Sun Genomics announces three new clinical tests as part of its CLIA-accredited laboratory. These tests, the Floré intestinal inflammation test, Gastrointestinal pathogen test flora, and Floré Heavy Metal Test are available on As Sun Genomics continues to expand its testing capabilities, the company will help a wider population identify and treat a variety of intestinal health issues.

At the Digital Medicine & MedTech Showcase, Jain will discuss the science around gut microflora and elaborate on the bridge between self-care and healthcare, especially as more and more people continue to consider their health gut as an important factor in their overall health.

“The more we can create personalized probiotic solutions rooted in whole-genome microflora testing results, the better we can help the hundreds of millions of people with gut health issues,” Jain said. “As more people become empowered to take control of their gut health and more physicians become aware of testing technology, we believe gut microflora testing will become the new standard of care. “

Digital Medicine & Medtech Showcase, as part of Biotech Showcase, is produced by Demy-Colton and EBD Group. The Showcase is an investor conference focused on advances in therapeutic development by providing a sophisticated networking platform for executives and investors fostering investment and partnership opportunities.

“We are delighted that Sun Genomics is participating in this year’s Digital Medicine & Medtech Showcase,” said Sara Demy, CEO of Demy-Colton. “Digital Medicine & Medtech Showcase is a great opportunity for today’s cutting-edge entrepreneurs and motivated investors to come together to discover the potential of technologies that will drive the future of the life sciences industry.”

Since its inception in 2016, Sun Genomics has served tens of thousands of customers with its Floré precision gut health offering. For more information about Sun Genomics, visit

Digital Medicine & Medtech Showcase is part of Biotech Showcase, which is an investor and networking conference dedicated to providing private and public biotech and life science companies the opportunity to showcase and meet with investors and executives pharmaceuticals in one place. Investors and biopharmaceutical executives from around the world come together in this landmark week that sets the tone for the year ahead. Now in its 14th year, Biotech Showcase is a well-established and well-respected conference offering several company presentation tracks, plenary sessions, workshops, networking, and the ability to schedule one-on-one meetings. Biotech Showcase and its family of events are produced by Demy-Colton and EBD Group. Both organizations have a long history of producing high quality programs that support the broader biotechnology and life sciences industry.

Sun Genomics, headquartered in San Diego, Calif., is a leader in gut health. Founded in 2016, the company specializes in gut health testing and tailored supplements based on an individual’s gut microflora. This approach ensures that customers receive a fully personalized gut health supplement delivered as part of a monthly subscription.

A photo accompanying this ad is available at

CONTACT: Media Contact Janine Warner Crowe PR (619) 794-0114, ext. 722

Comments are closed.